Aaron D Fobian1, Dustin M Long2, Jerzy P Szaflarski3. 1. Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham (UAB), Birmingham, Alabama. 2. Department of Biostatistics, University of Alabama at Birmingham (UAB), Birmingham, Alabama. 3. Departments of Neurology, Neurosurgery and Neurobiology, The UAB Epilepsy Center, University of Alabama at Birmingham (UAB), Birmingham, Alabama.
Abstract
OBJECTIVE: Our aim was to conduct a pilot randomized controlled trial of a novel cognitive behaviorally based intervention for pediatric PNES called Retraining and Control Therapy (ReACT). METHODS: Participants were randomized to receive either eight sessions of ReACT or supportive therapy, and participants completed follow-up visits at 7- and 60-days posttreatment. The primary outcome measure was PNES frequency at 7-days posttreatment. Eligibility criteria included children with video-EEG confirmed PNES and participant/parent or guardian willingness to participate in treatment. Exclusion criteria included substance use, psychosis, and severe intellectual disability. Forty-two patients were assessed for eligibility and 32 were randomized. ReACT aimed to retrain classically conditioned, involuntary PNES by targeting catastrophic symptom expectations and a low sense of control over symptoms using principles of habit reversal. Supportive therapy was based on the assumption that relief from stress or problems can be achieved by discussion with a therapist. RESULTS:Twenty-nine participants (Mage = 15.1 years, SDage = 2.5; 72.2% female; 57.1% Caucasian, 28.6% African American) completed 7-days postprocedures. For PNES frequency, the Wilcoxon Rank Sum test statistic was 273.5 yielding a normal approximation of Z = 4.725 (P < 0.0001), indicating a significant improvement in PNES frequency for ReACT at 7-days posttreatment compared to supportive therapy. Participants with PNES in the 7-days posttreatment were removed from the study for additional treatment, resulting in no 60-day follow-up data for supportive therapy. INTERPRETATION:ReACT resulted in significantly greater PNES reduction than supportive therapy, with 100% of patients experiencing no PNES in 7 days after ReACT. Additionally, 82% remained PNES-free for 60 days after ReACT.
RCT Entities:
OBJECTIVE: Our aim was to conduct a pilot randomized controlled trial of a novel cognitive behaviorally based intervention for pediatric PNES called Retraining and Control Therapy (ReACT). METHODS:Participants were randomized to receive either eight sessions of ReACT or supportive therapy, and participants completed follow-up visits at 7- and 60-days posttreatment. The primary outcome measure was PNES frequency at 7-days posttreatment. Eligibility criteria included children with video-EEG confirmed PNES and participant/parent or guardian willingness to participate in treatment. Exclusion criteria included substance use, psychosis, and severe intellectual disability. Forty-two patients were assessed for eligibility and 32 were randomized. ReACT aimed to retrain classically conditioned, involuntary PNES by targeting catastrophic symptom expectations and a low sense of control over symptoms using principles of habit reversal. Supportive therapy was based on the assumption that relief from stress or problems can be achieved by discussion with a therapist. RESULTS: Twenty-nine participants (Mage = 15.1 years, SDage = 2.5; 72.2% female; 57.1% Caucasian, 28.6% African American) completed 7-days postprocedures. For PNES frequency, the Wilcoxon Rank Sum test statistic was 273.5 yielding a normal approximation of Z = 4.725 (P < 0.0001), indicating a significant improvement in PNES frequency for ReACT at 7-days posttreatment compared to supportive therapy. Participants with PNES in the 7-days posttreatment were removed from the study for additional treatment, resulting in no 60-day follow-up data for supportive therapy. INTERPRETATION: ReACT resulted in significantly greater PNES reduction than supportive therapy, with 100% of patients experiencing no PNES in 7 days after ReACT. Additionally, 82% remained PNES-free for 60 days after ReACT.
Authors: W C LaFrance; G I Keitner; G D Papandonatos; A S Blum; J T Machan; C E Ryan; I W Miller Journal: Neurology Date: 2010-08-25 Impact factor: 9.910
Authors: Mark J Edwards; Giovanna Moretto; Petra Schwingenschuh; Petra Katschnig; Kailash P Bhatia; Patrick Haggard Journal: Neuropsychologia Date: 2011-06-06 Impact factor: 3.139
Authors: Laura H Goldstein; Alicia C Deale; Sara J Mitchell-O'Malley; Brian K Toone; John D C Mellers Journal: Cogn Behav Neurol Date: 2004-03 Impact factor: 1.600
Authors: Laura H Goldstein; Emily J Robinson; John D C Mellers; Jon Stone; Alan Carson; Markus Reuber; Nick Medford; Paul McCrone; Joanna Murray; Mark P Richardson; Izabela Pilecka; Carole Eastwood; Michele Moore; Iris Mosweu; Iain Perdue; Sabine Landau; Trudie Chalder Journal: Lancet Psychiatry Date: 2020-05-20 Impact factor: 27.083
Authors: David L Perez; Timothy R Nicholson; Ali A Asadi-Pooya; Indrit Bègue; Matthew Butler; Alan J Carson; Anthony S David; Quinton Deeley; Ibai Diez; Mark J Edwards; Alberto J Espay; Jeannette M Gelauff; Mark Hallett; Silvina G Horovitz; Johannes Jungilligens; Richard A A Kanaan; Marina A J Tijssen; Kasia Kozlowska; Kathrin LaFaver; W Curt LaFrance; Sarah C Lidstone; Ramesh S Marapin; Carine W Maurer; Mandana Modirrousta; Antje A T S Reinders; Petr Sojka; Jeffrey P Staab; Jon Stone; Jerzy P Szaflarski; Selma Aybek Journal: Neuroimage Clin Date: 2021-03-11 Impact factor: 4.881